Subject: NIH GUIDE Vol l9, No.24, June 29, l990
From: Dot Baker <[email-masked]>
To: [email-masked]
Date: Thu, 28 Jun 90 13:04 EST

Hello Paul,
   This is one of two articles coming to you today from the June 29th
NIH Guide.  Please post this one to the listserver as:
   NIHGUIDE.062990
 Thanks,  Have a nice day.
                          Dottie
 ---------------------------- Text of forwarded message -----------------------
     
X-comment: NIH Guide (including TOC) contained 4 pages (320 lines)
X-comment: RFAs described:  CA-90-18

     

     
NIH GUIDE - Vol. 19, No. 24, June 29, 1990

                   NOTICES OF AVAILABILITY (RFPs AND RFAs)

CENTRAL IMMUNOLOGY LABORATORY FOR AIDS VACCINE CLINICAL TRIALS (RFP) ........ 1
National Institute of Allergy and Infectious Diseases       (84/117)
Index:  ALLERGY, INFECTIOUS DISEASES

DCBDC SMALL RESEARCH GRANTS ON ANIMAL MODELS OF SOLID TUMORS
(RFA CA-90-18) .......................................(120/212, 324/662)..... 1
National Cancer Institute
Index:  CANCER

                        ONGOING PROGRAM ANNOUNCEMENTS

NIMH FUNCTIONAL BRAIN IMAGING CENTERS FOR THE STUDY OF MENTAL
DISORDER (PA-90-18) ..................................(218/265).............. 2
National Institute on Mental Health
Index:  MENTAL HEALTH

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

                   NOTICES OF AVAILABILITY (RFPs AND RFAs)

CENTRAL IMMUNOLOGY LABORATORY FOR AIDS VACCINE CLINICAL TRIALS
     
RFP AVAILABLE:  RFP-NIH-NIAID-DAIDS-91-13
     
P.T. 34; K.W. 0715008, 0740075, 0710070, 0780010, 0755010
     
National Institute of Allergy and Infectious Diseases
     
The National Institute of Allergy and Infectious Diseases (NIAID), NIH, has a
requirement to perform routine and innovative immunologic and virologic assays
to support AIDS vaccine trials undertaken by the NIAID AIDS Vaccine Clinical
Trials Network.  This NIAID-sponsored project will take approximately five (5)
years to complete.  A cost-reimbursement contract is anticipated, and one (1)
award will be made.
     
This is an announcement for an anticipated Request for Proposal (RFP).
RFP-NIH-NIAID-DAIDS-91-13 shall be issued on or about July 12, 1990, with a
closing date tentatively set for September 12, 1990.
     
Requests for the RFP should be directed in writing to:
     
Ms. Jacqueline Johnson
Contract Management Branch
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Control Data Building, Room 222P
6003 Executive Blvd.
Bethesda, MD  20892
     
To receive a copy of the RFP, please supply this office with two (2)
self-addressed labels.  All responsible sources may submit a proposal which
will be considered.
     
This advertisement does not commit the Government to award a contract.

DCBDC SMALL RESEARCH GRANTS ON ANIMAL MODELS OF SOLID TUMORS
     
RFA AVAILABLE:  CA-90-18
     
P.T. 34; K.W. 0715035, 0755020, 0710070
     
National Cancer Institute
     
Letter of Intent Receipt Date:  September 1, 1990
Application Receipt Date:  October 10, 1990
     
INTRODUCTION
     
The Cancer Immunology Branch of the Division of Cancer Biology, Diagnosis, and
Centers (DCBDC) of the National Cancer Institute (NCI) invites applications
for small grants to develop and establish animal models of solid tumors of
non-hemopoietic origin to improve our understanding of the complexities of the
human immune response to these tumors.  Models are sought which demonstrate
similar biological characteristics to human cancer, and which could be used in
future studies to analyze the immunobiology of host-tumor interactions.  The
present Request for Applications (RFA) announcement is for a single
solicitation with a specified deadline (October 10, 1990) for receipt of
applications and September 1, 1990, for receipt of letters of intent.
     
RESEARCH GOALS AND SCOPE
     
The goal of this initiative is to provide funds for the development of new, or
further characterization of existing, animal models of solid tumors of
non-hematopoietic origin which are relevant to human cancer.  The initiative
is not limited to small laboratory animals (e.g., mice); however, appropriate
reagents, such as antibodies for cellular identification, must be available
for the immunologic study of any animal model proposed.
     
The scope of this initiative may comprise the use of transgenic animals, mice
with the severe combined immunodeficiency (SCID) defect, spontaneously arising
tumors, transplantable tumors from the site of origin to the same site within
the recipient, or other tumor systems developed by the applicant.  Tumors
induced by chemicals, viruses or radiation will be considered if the tumor
type exhibits characteristics analogous to a human tumor.  Animal models which
     
             NIH GUIDE - Vol. 19, No. 24, June 29, 1990 - Page 1
utilize congenitally athymic (nude) mice where human tumors are injected
subcutaneously into these mice primarily for maintaining the tumor will be
excluded from review, and those applications will be returned to the
applicant.
     
MECHANISM OF SUPPORT
     
Support of this program will be through the National Institutes of Health
(NIH) grant-in-aid.  Applicants will be responsible for the planning,
direction, and execution of the proposed project.  Except as otherwise stated
in this RFA, awards will be administered under PHS policy as stated in the
Public Health Service Grants Policy statement, DHHS Publication No. (OASH)
82-50,000, revised January 1, 1987.  This RFA is a one-time solicitation.
     
The small grants (R03) mechanism provides research support specifically
limited in time and amount for studies in categorical program areas.  Small
grants provide flexibility for initiating studies, which are generally for
preliminary short-term projects and are non-renewable.  Furthermore, the time
interval from application to funding is shortened under the R03 mechanism,
thus allowing new ideas to be investigated or pursued in a more expeditious
manner.
     
Approximately $700,000 in total costs per year for three years will be
committed specifically to fund applications which are submitted in response to
this RFA.  The total direct costs per application may not exceed $50,000 per
year.  It is anticipated that approximately 10 awards will be made.  This
funding level is dependent on the receipt of a sufficient number of
applications of high scientific merit.  The total project period for
applications submitted in response to this RFA should be at least one (1) year
and may not exceed two (2) years.  The earliest feasible start date for awards
will be April 1, 1991.  Although this program is provided for in the financial
plans of the NCI, the award of grants pursuant to this RFA is also contingent
upon the availability of funds for this purpose.
     
INQUIRIES
     
Prospective applicants are strongly encouraged to discuss their ideas with Dr.
John Finerty (see below) to determine whether they fit the definition and
guidelines of this announcement.  The Program Director welcomes the
opportunity to discuss this RFA with potential applicants.  For further
information, prospective applicants should contact:
     
Dr. John F. Finerty
Program Director
Cancer Immunology Branch
National Cancer Institute
National Institutes of Health
Executive Plaza South, Room 634
6120 Executive Boulevard
Rockville, MD  20892
Telephone:  (30l) 496-78l5
FAX:  30l-496-8656

                        ONGOING PROGRAM ANNOUNCEMENTS

NIMH FUNCTIONAL BRAIN IMAGING CENTERS FOR THE STUDY OF MENTAL DISORDER
     
PA:  PA-90-18
     
P.T. 34; K.W. 0706030, 0705010, 0715129
     
National Institute on Mental Health
     
The purpose of this announcement is to establish core resource Centers
dedicated to multidisciplinary research using Positron Emission Tomography
(PET) methodology in conjunction with other existing brain imaging
technologies.  The Center Grant will provide support for purchasing the
necessary equipment to establish a PET capability or, where such capability
already exists, support will be provided to assure access to such equipment by
mental health researchers.
     
Applications may be submitted by any public or private, nonprofit or
for-profit organization, including units of State and local governments.
Women and minority investigators are especially encouraged to apply.

     
             NIH GUIDE - Vol. 19, No. 24, June 29, 1990 - Page 2
Applicants are urged to consider the inclusion of minorities and women in
study populations for all research efforts.  If they are not to be included, a
clear rationale for their exclusion should be provided.
     
It is estimated that approximately $5 million will be available to support
approximately two new grants under this announcement in fiscal year 1991.  The
exact amount will depend on appropriated funds, the quality of proposals, and
program priorities at the time of the award.
     
Applications will be assigned following the usual PHS referral guidelines.
     
To qualify for fiscal year 1991 funding, applications must be submitted by
October 1, 1990.  In subsequent years, a similar timetable will be in effect,
using the October 1 receipt date.
     
Prior to submission, applicants are encouraged to contact:
     
Henry Khachaturian, Ph.D.
Neuroimaging and Applied Neuroscience Research Branch
Division of Basic Brain and Behavioral Sciences
National Institute of Mental Health
Room 11-105, Parklawn Building
5600 Fishers Lane
Rockville, MD  20857
Telephone:  (301) 443-3948

**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF
RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS THE
CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH.  APPLICANTS WHO
USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO FOLLOW THE CARRIER'S
REQUIREMENTS FOR SHOWING A STREET ADDRESS.  THE ADDRESS FOR THE WESTWOOD
BUILDING IS:
     
5333 Westbard Avenue
Bethesda, Maryland 20816

     

     

     

     

     

     

     

     

     

     

     

     

     

     
     
             NIH GUIDE - Vol. 19, No. 24, June 29, 1990 - Page 3